The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.

Gilead Sciences (NASDAQ:GILD) announced Tuesday that the European Commission has approved its biannual injection for HIV ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.

In this article, we will take a detailed look at the Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings.

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

This quiet truth is what made the presence of Gilead Sciences – a biopharmaceutical company primarily known for its work in developing and delivering innovative therapies for diseases like HIV ...

Shares of Gilead Sciences Inc. GILD shed 2.73% to $113.03 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.02% to 6,389.77 ...